SEC Form 4 · accession 0001104659-16-160131
Adaptimmune Therapeutics PLC · ADAP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tal Zvi Zaks
Director
Period of report
Nov 29, 2016
Accepted (ET)
Dec 1, 2016 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase Ordinary SharesF1,F2 | $0.81 | Nov 29, 2016 | A | 288,000 | A | — | Nov 29, 2026 | Ordinary Shares | 288,000 | 288,000 | D |
Explanation of responses
- F1The exercise price was converted from GBP0.65 based on the closing midpoint exchange rate for the U.S. dollar on the trading day prior to the date of grant listed in the Financial Times. The actual exercise price will be the pounds sterling amount.
- F2Exercisable as to 72,000 Ordinary Shares on November 29, 2017 and will be exercisable as to the remainder in monthly installments of 9,000 Ordinary Shares on the twenty-ninth of each month from December 29, 2017 through November 29, 2019.